Biodexa Pharmaceuticals Released Patient Updates On Progression-free Survival And Overall Survival From The Ongoing MAGIC-1 Study Of MTX110 In Recurrent Glioblastoma, Says In A Small But Important Phase 1 Study, MTX110 Is Outperforming Historic Norms Of Progression-free And Overall Survival
Portfolio Pulse from Benzinga Newsdesk
Biodexa Pharmaceuticals has released promising patient updates from the ongoing MAGIC-1 study of MTX110 in recurrent glioblastoma. The Phase 1 study shows MTX110 outperforming historical norms in progression-free and overall survival.
October 17, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biodexa Pharmaceuticals' MTX110 is showing promising results in a Phase 1 study for recurrent glioblastoma, outperforming historical norms in progression-free and overall survival.
The positive results from the Phase 1 study of MTX110 in recurrent glioblastoma suggest potential efficacy, which could lead to increased investor confidence and a positive impact on BDRX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90